SCHEDULE: Matrix Capital Discloses 3.5% Stake in Maze Therapeutics
Beneficial Ownership Report
Matrix Capital Management Company, LP and David E. Goel have reported a 3.5% beneficial ownership stake in Maze Therapeutics, Inc., holding 1,653,684 shares of common stock.
Summary
- Matrix Capital Management Company, LP and David E. Goel have filed an Amendment No. 1 to Schedule 13G, disclosing their beneficial ownership in Maze Therapeutics, Inc.
- The reporting persons collectively beneficially own 1,653,684 shares of Maze Therapeutics' common stock.
- This ownership represents 3.5% of the total outstanding shares of Maze Therapeutics.
- The percentage is calculated based on 47,850,886 shares outstanding, which includes 43,850,884 shares as of August 6, 2025, and an additional 4,000,002 shares issued in a private placement.
- The event requiring this filing occurred on September 30, 2025.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership disclosure (Schedule 13G) and does not contain qualitative information that would significantly sway sentiment. It is a factual report of an institutional investor's stake.
Positives
- NA The filing is a factual disclosure of ownership and does not inherently contain positive operational or financial results. The presence of a notable institutional investor could be perceived as a positive signal by the market.
Negatives
- NA The filing is a factual disclosure of ownership and does not inherently contain negative operational or financial results.
Risks
- NA The filing is a beneficial ownership report and does not detail specific risks related to Maze Therapeutics, Inc.'s operations or financial health.
Future Outlook
NA This filing does not contain any forward-looking statements or guidance from the issuer.
Management Comments
- NA This filing contains signatures from the reporting persons, not management comments from Maze Therapeutics.
Industry Context
This filing indicates an institutional investor's position in a biotechnology company, Maze Therapeutics. While the filing itself doesn't provide industry analysis, the investment by Matrix Capital Management, a notable investment firm, could be interpreted by the market as a vote of confidence in the biotech sector or Maze Therapeutics specifically, especially given the company's recent private placement.
Comparison to Industry Standards
- NA This filing is a disclosure of beneficial ownership and does not provide operational or financial results for comparison to industry standards or specific comparable companies/projects.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
Legal Proceedings
- NA The filing does not report any legal or regulatory matters.
Related Party Transactions
- NA The filing does not disclose any related party dealings.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by an institutional investor like Matrix Capital Management could be viewed positively by existing shareholders, potentially signaling confidence in the company's prospects.
- Potential Investors: The filing provides transparency regarding institutional ownership, which can influence investment decisions.
Next Steps
- NA The filing does not mention any specific future actions, events, or milestones for Maze Therapeutics or the reporting persons beyond their ongoing filing obligations.
Key Dates
| Date | Description |
|---|---|
| 2025-06-30 | End of quarterly period for which Maze Therapeutics' Form 10-Q reported 43,850,884 shares outstanding. |
| 2025-08-06 | Date as of which 43,850,884 shares of Maze Therapeutics were reported outstanding in the Company's Quarterly Report on Form 10-Q. |
| 2025-08-12 | Date Maze Therapeutics filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, with the SEC. |
| 2025-09-11 | Date Maze Therapeutics filed a Current Report on Form 8-K with the SEC, describing the issuance of 4,000,002 shares in a private placement. |
| 2025-09-30 | Date of event which required the filing of this Schedule 13G statement. |
| 2025-11-13 | Date the Schedule 13G/A filing was signed by Matrix Capital Management Company, LP and David E. Goel. |
Keywords
Maze Therapeutics, Matrix Capital Management, David E. Goel, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology, Healthcare
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.